TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
14 août 2024 08h30 HE
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Crnic Institute Clinical Trial Shows JAK Inhibitor Improves Multiple Autoimmune Conditions in Patients with Down Syndrome
13 août 2024 13h48 HE
|
Global Down Syndrome Foundation
Denver, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to support a new study published in eLIFE by researchers from its partner and Affiliate, the Linda...
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
13 août 2024 07h00 HE
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
08 août 2024 19h20 HE
|
HilleVax, Inc.
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine...
Breakthrough Study Reveals Molecular Subtypes of Down Syndrome, Offering Insights for Personalized Medicine Approaches
07 août 2024 16h27 HE
|
Global Down Syndrome Foundation
Denver, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Global Down Syndrome Foundation (GLOBAL) is proud to support a new study published in Nature Communications by researchers at its partner and Affiliate,...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29 juil. 2024 09h15 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
29 juil. 2024 08h00 HE
|
Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
25 juil. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
25 juil. 2024 05h00 HE
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...